Bone Biologics Corp. (NASDAQ:BBLG – Get Free Report) was the recipient of a significant drop in short interest in August. As of August 31st, there was short interest totaling 36,999 shares, a drop of 76.4% from the August 15th total of 156,590 shares. Approximately 1.4% of the company’s stock are sold short. Based on an average trading volume of 89,427 shares, the days-to-cover ratio is currently 0.4 days.
Institutional Inflows and Outflows
An institutional investor recently raised its position in Bone Biologics stock. DRW Securities LLC increased its position in Bone Biologics Corp. (NASDAQ:BBLG – Free Report) by 113.8% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 23,576 shares of the company’s stock after purchasing an additional 12,549 shares during the quarter. DRW Securities LLC owned approximately 1.31% of Bone Biologics worth $34,000 as of its most recent SEC filing. Hedge funds and other institutional investors own 34.30% of the company’s stock.
Bone Biologics Stock Performance
Shares of NASDAQ:BBLG traded down $0.01 during trading on Friday, hitting $0.55. 11,288 shares of the stock were exchanged, compared to its average volume of 72,418. Bone Biologics has a 1-year low of $0.54 and a 1-year high of $2.89. The company has a market capitalization of $1.52 million, a price-to-earnings ratio of -0.40 and a beta of 0.89. The company’s fifty day simple moving average is $0.87 and its 200-day simple moving average is $1.13.
Wall Street Analyst Weigh In
Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Bone Biologics in a research report on Friday, July 24th. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat, the company has an average rating of “Sell”.
Read Our Latest Stock Report on BBLG
Bone Biologics Company Profile
Bone Biologics, Inc (NASDAQ: BBLG) is a clinical-stage biotechnology company focused on the development of cell-based therapies for skeletal repair and regeneration. The company’s research efforts center on both allogeneic and autologous mesenchymal cell platforms designed to enhance bone healing in patients with orthopedic injuries and degenerative bone conditions. Its approach aims to provide alternatives to traditional grafting procedures by harnessing the regenerative potential of specialized stem cells.
Leveraging proprietary cell expansion and delivery technologies, Bone Biologics is advancing a pipeline of investigational therapies targeting indications such as spinal fusion, long-bone non-union and maxillofacial defects.
Further Reading
- Five stocks we like better than Bone Biologics
- Rocket Lab Tackles a Supply Chain Bottleneck as the Stock Hunts for a Bottom. Time to Buy?
- Optical Cable Corporation Is Starting to Get the Market’s Attention
- Oil Above $100 Is Creating a New Opportunity Beyond the Major Producers
- Is Nike’s Index Demotion a Warning or a Buying Opportunity?
Receive News & Ratings for Bone Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bone Biologics and related companies with MarketBeat.com's FREE daily email newsletter.
